After raking in billions of dollars from their experimental COVID vaccine, Pfizer is back for more – revealing a dangerous new vaccine which is specifically designed to target unborn babies.
Pfizer announced that they are working on a new vaccine which will be injected into pregnant mothers in order to inoculate their unborn babies while they are still in the womb.
According to the pharmaceutical giant, the vaccine is supposed to protect children against the respiratory syncytial virus (RSV) after birth.
RSV can be deadly for some infants, but the large majority tend to recover from the common virus quite easily, suggesting a vaccine like this may not offer too much benefit to most children.
“Pfizer Inc. today announced positive top-line data from the Phase 3 clinical trial (NCT04424316) MATISSE (MATernal Immunization Study for Safety and Efficacy) investigating its bivalent RSV prefusion vaccine candidate, RSVpreF or PF-06928316, when administered to pregnant participants to help protect their infants from RSV disease after birth,” Pfizer announced on its website.
“MATISSE is an ongoing randomized, double-blinded, placebo-controlled Phase 3 study designed to evaluate the efficacy, safety, and immunogenicity of RSVpreF against medically attended lower respiratory tract illness (MA-LRTI) and severe MA-LRTI in infants born to healthy women vaccinated during pregnancy,” Pfizer said.
Pfizer claims that the RSVpreF investigational vaccine was “well-tolerated with no safety concerns for both vaccinated individuals and their newborns,” but that’s the same thing they said about the COVID vaccines which have now been proven to be extremely dangerous.
According to the company, “Pfizer is the only company with an investigational vaccine being prepared for regulatory applications for both infants through maternal immunization and older adults to help protect against RSV”
“These data reinforce Pfizer’s resolve to bring our expertise in the research and development of innovative vaccines to address critical public health needs using new approaches and technologies.”
The results of the study met only one of the pre-specified regulatory success criteria, but Pfizer plans to submit its first regulatory application by end of 2022.
As measured by severe medically attended lower respiratory tract (MA-LRTI) illness through the first 90 days of life, the committee found an efficacy of 81.8% (CI: 40.6%, 96.3%). The number fell to 69.4% over the six-month follow-up period.
Pfizer’s history, however, proves that they have a rather… intimate relationship with the FDA, suggesting the federal agency could help Pfizer cut some corners in order to bring this dangerous new vaccine to market, and that’s further evidenced by the fact that Pfizer’s RSVpreF was already granted a breakthrough therapy designation by the FDA.